Company intelligence / Profile preview

Causeway Therapeutics

Glasgow, Scotland, United Kingdomcausewaytx.com ↗

Ownership: Private
Employees: ~9
Development stage: Phase 2

Overview

TenoMiR, a one-time injectable miR29a mimic, has shown significant improvement in tendon healing in preclinical models. It is currently being evaluated in a Phase II trial for tennis elbow/lateral epicondylitis. There are no approved therapies for tendinopathy; TenoMiR aims to address this unmet need by restoring normal tendon structure through microRNA modulation. Early data indicate potential to improve function and reduce pain.

Therapeutic areas: CardiovascularDermatologyRheumatology
Modalities: microRNA therapeutics (miRNA)nucleic acid therapies
Industry: Biotech

Drug pipeline

3 assets

TenoMiR

2 more assets in the full pipeline.

Partnerships

Scottish Enterprise / Scottish Investment Bank – co-investors/supporters of early development and commercialization efforts

Beyond the preview

Go deeper on Causeway Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Causeway Therapeutics.